Physician profile
R Allen Baum
NPI 1013994987
$3,721.61
in general payments reported to CMS, 2019-2025
26 companies · $640 in 2025
The $640 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $57.99 · 2021: $842 · 2022: $530 · 2023: $747 · 2024: $550 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $824.80 | 2020-2025 | |
| Boston Scientific Corporation | $702.97 | 2019-2025 | Cds - Mct/Cem Monitoring, Bodyguardian, Watchman Access System |
| Pfizer INC. | $327.57 | 2022-2025 | |
| Medtronic, INC. | $224.17 | 2022 | |
| Amarin Pharma, INC. | $212.93 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $208.55 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $157.73 | 2021-2023 | Verquvo |
| Heartflow, INC. | $130.39 | 2021 | |
| Cvrx, INC. | $129.97 | 2023 | Barostim Neo System |
| Esperion Therapeutics, INC. | $94.33 | 2020-2021 | |
| Amgen INC. | $91.06 | 2024-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.17 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $85.75 | 2024-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $65.86 | 2022-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $60.77 | 2024 | Arcalyst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $50.37 | 2022-2025 | |
| Atricure, INC. | $48.97 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.89 | 2024-2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $31.64 | 2025 | Optimizer |
| Novo Nordisk INC | $25.10 | 2025 | Wegovy |
| Irhythm Technologies, INC. | $23.81 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $21.96 | 2021 | |
| Agepha Pharma Fz LLC | $19.97 | 2024 | Lodoco |
| Glaxosmithkline, LLC. | $17.92 | 2025 | Shingrix, Arexvy |
| Preventice Services, LLC | $16.80 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw R Baum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.